PP Tetra Bio-Pharma Related News
Next generation pharmacology research with Tetra Bio-Pharma
Tetra Bio-Pharma are pleased to announce their co-development agreement with MAKScientific – could this agreement be the advancements needed for next generation pharmacology research?
Leaders...
Tetra confirms FDA conditions met for CAUMZ drug
FDA conditions met for Fast Track programme where the patient population has a serious condition with significant morbidity.
Leaders in botanical-derived drug discovery and development,...
Tetra Bio Pharma receives approval for OTC use in pain drugs
TERPACAN™, from Tetra Bio Pharma, has received approval for over the counter (OTC) use in back and muscle pain, and in hemorrhoids.
TERPACAN™ is expected...
Want to hear the latest developments regarding Tetra’s hepatocellular carcinoma drug?
Responsible for 80% of primary malignant liver tumours in adults, hepatocellular carcinoma is a common form of liver cancer – but did you know...
Tetra Bio-Pharma: global developer of cannabinoid-derived products
Dr Guy Chamberland explains how Tetra Bio-Pharma is taking a pharmaceutical pathway to discovering and developing cannabinoid-derived products.
In an industry that could aptly be...
Treatment of pain and inflammation with Tetra Bio-Pharma’s CAUMZ kit
CAUMZ is a non-opioid alternative in Phase 3 development for the treatment of pain and inflammation, and Tetra are one step closer to bringing...
Discover the joint venture to develop therapeutics targeting chronic inflammatory conditions
Therapeutics for chronic inflammatory conditions may come sooner than you think as Tetra Bio-Pharma announce joint venture with Thorne and Onegevity Health to form...
Cannabinoid-based drug discovery and development is about to get an upgrade
Tetra Bio-Pharma, engaged in cannabinoid-based drug discovery & development, recently acquired Panag Pharma, creating a new strategic partnership delving further into the cannabis industry.
PANAG...
